Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 46.34 percent. This is a 50 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $301.000 thousand which missed the analyst consensus estimate of $931.143 thousand by 67.67 percent.